NCT00527605View on ClinicalTrials.gov

Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)

PHASE3CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Benign Prostatic HyperplasiaProstatic Hyperplasia
Interventions
DRUG

Dutasteride 0.5mg capsule

Dutasteride 0.5mg once daily orally

DRUG

Dutasteride matched placebo

Dutasteride matched placebo once daily orally

Trial Locations (12)

100034

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

100853

GSK Investigational Site, Beijing

200001

GSK Investigational Site, Shanghai

200025

GSK Investigational Site, Shanghai

200030

GSK Investigational Site, Shanghai

210006

GSK Investigational Site, Nanjing

300211

GSK Investigational Site, Tianjin

310003

GSK Investigational Site, Hangzhou

430030

GSK Investigational Site, Wuhan

510180

GSK Investigational Site, Guangzhou

Unknown

GSK Investigational Site, Beijing

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY